ArticleScientific reports2026
Optimization and evaluation of gastro-expandable film of Eudragit S100 and ethylcellulose by using the design of experiment.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of the present study was to develop and optimize a gastroretentive expandable film system of itopride hydrochloride using ethylcellulose and Eudragit S100 as film-forming polymers and triethyl citrate as a plasticizer, in order to enhance gastric retention and oral bioavailability. The gastroretentive expandable film was prepared by the solvent-casting method using a solvent system comprising ethanol and dichloromethane (1:1). A 2-factor, 3-level central composite design was employed to optimize the formulation variables. The prepared films were characterized using FTIR, DSC, XRD, and SEM to evaluate drug-excipient compatibility and solid-state properties. The films were assessed for folding endurance, floating time, in-vitro drug release, and gastroretention behavior. In-vivo pharmacokinetic studies were conducted in New Zealand white rabbits, and pharmacokinetic parameters (Cmax, Tmax, AUC, MRT, and t1/2) were determined from plasma concentration–time profiles. Stability studies were performed on the optimized formulation. The optimized expandable film demonstrated excellent mechanical strength with a folding endurance of 146 ± 2.1, rapid floating (9 ± 0.45 min), and nearly complete in-vitro drug release (98.9 ± 0.27%). The formulation exhibited gastroretention for more than 8 h. In-vivo pharmacokinetic evaluation revealed improved absorption, with a relative bioavailability of 106.14% compared to the marketed formulation (GANATON SR). The optimized film remained stable under storage conditions, as confirmed by stability studies. The developed gastroretentive expandable film system of itopride hydrochloride successfully achieved prolonged gastric retention, enhanced drug release, and improved oral bioavailability. This delivery system represents a promising and stable alternative to conventional sustained-release formulations for drugs requiring extended gastric residence.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.